Rationale: Incident pulmonary arterial hypertension was underrepresented in most pulmonary
hypertension registries and may have a different disease profile to prevalent disease. …

With significant therapeutic advances in the field of pulmonary arterial hypertension, the
need to identify clinically relevant treatment goals that correlate with long-term outcome has …

Background— Impaired endothelial homeostasis underlies the pathophysiology of pulmonary
arterial hypertension (PAH). We speculated that PAH patients are deficient in circulating …

Background Macitentan is beneficial for long-term treatment of pulmonary arterial
hypertension. The microvasculopathy of chronic thromboembolic pulmonary hypertension (CTEPH) …

Objectives : This study sought to understand the prevalence and clinical relevance of iron
缺乏在特发性肺患者rterial hypertension (IPAH). Background : Iron …

…Luke S Howard2, … If you wish to reuse any or all of this article please use the link below
which will take you to the Copyright Clearance Center’sRightsLink service. You will be able to …

Patients with suspected pulmonary hypertension (PH) should be evaluated using a multimodality
approach to ensure that they receive a correct diagnosis. The series of investigations …

Rationale: MicroRNAs (miRNAs or miRs) are implicated in the pathogenesis of various
cardiovascular diseases, including pulmonary arterial hypertension (PAH). Objectives: We …

Pulmonary arterial hypertension (PAH) is a rare, debilitating and rapidly progressive disease.
尽管有important medical advances in PAH management, the search …

Background: Pulmonary arterial hypertension (PAH) is a heterogeneous disorder with high
mortality. Methods: We conducted a comprehensive study of plasma metabolites using …